$2.05 Billion is the total value of Camber Capital Management LP's 35 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 59.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | Sell | SPDR S&P 500 ETF Trustput | $241,800,000 | -65.8% | 1,000,000 | -66.7% | 11.77% | -59.0% |
| TEVA | Buy | TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)adr | $174,951,000 | +4.5% | 5,266,450 | +1.0% | 8.52% | +25.5% |
| MYL | Buy | MYLAN NV | $164,825,000 | +2.0% | 4,245,889 | +2.4% | 8.02% | +22.4% |
| GILD | Buy | GILEAD SCIENCES, INC.call | $141,560,000 | +108.4% | 2,000,000 | +100.0% | 6.89% | +150.2% |
| GILD | Buy | GILEAD SCIENCES, INC. | $141,560,000 | +9.7% | 2,000,000 | +5.3% | 6.89% | +31.7% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $104,593,000 | -17.5% | 5,350,000 | -0.9% | 5.09% | -0.9% |
| AGN | Sell | ALLERGAN PLC | $85,082,000 | -18.3% | 350,000 | -19.7% | 4.14% | -1.9% |
| GHDX | GENOMIC HEALTH INC | $80,011,000 | +3.4% | 2,458,100 | 0.0% | 3.90% | +24.0% | |
| BKD | Sell | BROOKDALE SENIOR LIVING | $79,434,000 | +7.5% | 5,400,000 | -1.8% | 3.87% | +29.1% |
| MYGN | Sell | MYRIAD GENETICS INC | $77,520,000 | -6.6% | 3,000,000 | -30.6% | 3.77% | +12.1% |
| THC | New | TENET HEALTHCARE CORP | $77,360,000 | – | 4,000,000 | +100.0% | 3.77% | – |
| SEM | SELECT MEDICAL HOLDINGS CORP | $76,750,000 | +15.0% | 5,000,000 | 0.0% | 3.74% | +38.0% | |
| BIVV | Buy | BIOVERATIV INC | $70,658,000 | +17.9% | 1,174,300 | +6.8% | 3.44% | +41.6% |
| OFIX | ORTHOFIX INTL N V | $69,720,000 | +21.8% | 1,500,000 | 0.0% | 3.39% | +46.2% | |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $45,105,000 | -36.5% | 350,000 | -46.2% | 2.20% | -23.8% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $43,823,000 | +9.7% | 1,300,000 | -3.7% | 2.13% | +31.6% |
| ENDP | Sell | ENDO INTL PLC | $39,922,000 | -29.2% | 3,574,000 | -29.3% | 1.94% | -15.0% |
| ELGX | Buy | ENDOLOGIX INC | $36,450,000 | -16.1% | 7,500,000 | +25.0% | 1.78% | +0.7% |
| TEVA | New | TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)call | $33,220,000 | – | 1,000,000 | +100.0% | 1.62% | – |
| AMAG | New | AMAG PHARMACEUTICALS INC | $31,280,000 | – | 1,700,000 | +100.0% | 1.52% | – |
| BIOS | BIOSCRIP INC | $27,639,000 | +59.7% | 10,180,000 | 0.0% | 1.35% | +91.7% | |
| BIIB | New | BIOGEN INC | $27,136,000 | – | 100,000 | +100.0% | 1.32% | – |
| ELOS | SYNERON MEDICAL LTD | $25,706,000 | +3.8% | 2,347,593 | 0.0% | 1.25% | +24.5% | |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $24,334,000 | – | 200,000 | +100.0% | 1.18% | – |
| AXGT | New | AXOVANT SCIENCES LTD | $23,190,000 | – | 1,000,000 | +100.0% | 1.13% | – |
| NVTA | INVITAE CORP | $22,926,000 | -13.6% | 2,398,123 | 0.0% | 1.12% | +3.7% | |
| EVHC | New | ENVISION HEALTHCARE CORP | $21,935,000 | – | 350,000 | +100.0% | 1.07% | – |
| AVXS | New | AVEXIS INC | $17,254,000 | – | 210,000 | +100.0% | 0.84% | – |
| RAD | New | RITE AID CORP | $14,750,000 | – | 5,000,000 | +100.0% | 0.72% | – |
| PTCT | Sell | PTC THERAPEUTICS | $9,165,000 | -25.5% | 500,000 | -60.0% | 0.45% | -10.6% |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $7,497,000 | +191.8% | 535,500 | +328.4% | 0.36% | +251.0% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $7,170,000 | +15.6% | 425,000 | -90.0% | 0.35% | +38.5% |
| BIOL | BIOLASE INC | $5,172,000 | -28.2% | 5,332,394 | 0.0% | 0.25% | -13.7% | |
| RDUS | New | RADIUS HEALTH INC | $4,523,000 | – | 100,000 | +100.0% | 0.22% | – |
| BIOL | BIOLASE INCcall | $0 | – | 1,841,173 | 0.0% | 0.00% | – | |
| DXTRQ | Exit | DEXTERA SURGICAL INC. | $0 | – | -837,483 | -100.0% | -0.04% | – |
| Exit | TARGACEPT INCnote | $0 | – | -1,684,799 | -100.0% | -0.07% | – | |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -650,000 | -100.0% | -0.98% | – |
| ALKS | Exit | ALKERMES PLC | $0 | – | -725,000 | -100.0% | -1.72% | – |
| ABT | Exit | ABBOTT LABS | $0 | – | -1,000,000 | -100.0% | -1.80% | – |
| CSII | Exit | CARDIOVASCULAR SYSTEMS INC | $0 | – | -1,750,000 | -100.0% | -2.01% | – |
| PRGO | Exit | PERRIGO CO PLC | $0 | – | -808,200 | -100.0% | -2.18% | – |
| LIVN | Exit | LIVANOVA PLC | $0 | – | -1,200,000 | -100.0% | -2.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.